Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda study shows long-term benefits of ulcerative colitis and Crohn’s therapy

Takeda study shows long-term benefits of ulcerative colitis and Crohn’s therapy

23rd February 2017

Takeda has announced interim findings from a long-term study that highlights the effectiveness of vedolizumab in the treatment of ulcerative colitis and Crohn's disease.

Data from the ongoing open-label GEMINI long-term safety study has shown that treatment with vedolizumab was associated with sustained clinical response and remission, in addition to health-related quality of life improvements, in patients with moderate to severely active ulcerative colitis and Crohn's disease.

These benefits were sustained over a five-year period, with vedolizumab shown to be significantly more effective than placebo at achieving lasting remission.

Data from real-world studies of this kind help to supplement the findings of randomised controlled studies when evaluating the clinical effectiveness and safety of drugs such as vedolizumab.

Professor Dr Severine Vermeire at University Hospitals Leuven said: "These latest findings underscore the consistent safety profile and effectiveness of vedolizumab as a long-term treatment option for adults with moderate to severely active ulcerative colitis and Crohn's disease."

Vedolizumab works by limiting the ability of certain white blood cells to infiltrate gut tissues, and is marketed under the brand name Entyvio.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801832755-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.